EMA strengthens safety measures for cenobmate in epilepsy

The European Medicines Agency (EMA) is tightening safety conditions for Ontozry, an antiepileptic drug containing cenobmate.

Published 8sem1 source

≈ 20sSpeed

The fact

These new rules aim to minimize the risk of serious adverse effects in treated patients.

The drug remains available but under strict clinical and biological monitoring.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on May 22, 2026